Conditions: Pulmonary Hypertension
Keywords: pre- and post-capillary pulmonary hypertension CpcPH
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 63
Healthy volunteers: no

Brief summary:
Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunction.

Detailed description:

Arms:
arm 1: oral tablet, 10 mg once daily. arm 2: Matching placebo, once daily.

Interventions: intervention 1: Macitentan intervention 2: Placebo
Intervention descriptions: intervention 1: oral tablet, 10 mg once daily intervention 2: matching placebo

Protocol document: